(Q38156262)

English

Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors

scientific article published on 29 October 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

0 references

pathophysiology

1 reference

based on heuristic

inferred from title

author name string

Peter Kruzliak

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Jan Novák

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Miroslav Novák

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

publication date

29 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Journal of Clinical Hypertension

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

3-13

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Mechanisms of angiogenesis and arteriogenesis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Molecular angiogenesis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Controversies in hypertension

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor and angiogenesis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor (VEGF) signaling in tumor progression

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Molecular mechanisms of VEGF-A action during tissue repair

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Comparing antibody and small-molecule therapies for cancer

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Managing patients treated with bevacizumab combination therapy.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

VEGF-Trap: a VEGF blocker with potent antitumor effects

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Developing aptamers into therapeutics

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Home blood-pressure monitoring in patients receiving sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Sorafenib for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Autocrine VEGF signaling is required for vascular homeostasis

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

VEGF inhibition and renal thrombotic microangiopathy

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Side effects of using nitrates to treat angina

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Recent developments in nitric oxide donor drugs.

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Nitric oxide and atherosclerosis: an update

1 reference

https://api.crossref.org/works/10.1093%2FAJH%2FHPT201

21 January 2018

Identifiers

10.1093/AJH/HPT201

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38156262&oldid=1744036024"